Takeo Fujii

8PUBLICATIONS
37CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsPredictive and prognostic markersHaematological tumoursCancer cell biology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Jan 27, 2026
Payload Diversification Overcomes Resistance and Guides Sequential Antibody-Drug Conjugate Therapy in Breast Cancer.

Dileep Reddy Rampa, Minji Seo, Nanae Ogata

|Dec 08, 2025
A Phase II Pilot Study of Anti-PD-L1, Durvalumab, and a PARP Inhibitor, Olaparib in Patients With Metastatic Triple-Negative Breast Cancer With or Without Germline BRCA Mutation.

Takeo Fujii, Ashley Cimino-Mathews, Stanley Lipkowitz

|Oct 18, 2025
Reconsidering the definition of triple-negative breast cancer in the immune checkpoint inhibitor era: an optimal cut-off value for hormone receptor percentage of HER2-negative invasive breast cancer.

Takeo Fujii, Toshiaki Iwase, Yu Shen

|Jul 16, 2025
Neutrophils drive vascular occlusion, tumour necrosis and metastasis.

Jose M Adrover, Xiao Han, Lijuan Sun

|Apr 25, 2025
Targeting metabolic vulnerability by combining NAMPT inhibitors and disulfiram for treatment of recurrent ovarian cancer.

Kei Kudo, Yoshimi Endo Greer, Daniel R Crooks

|Mar 13, 2025
Efficiency of Fulvestrant Monotherapy After CDK4/6 Inhibitor Exposure: Is This a Viable Choice?

Nanae Ogata, Brian G Barnett, Nicholas J H Sharp

Pageof 2

Frequent Collaborators

3 joint publications

Naoto T Ueno

2 joint publications

Nanae Ogata

2 joint publications

Stanley Lipkowitz

1 joint publications

Dileep Reddy Rampa